Harbour BioMed Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ — Harbour BioMed (“HBM” or the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual financial results of full year 2023. “We made progress in two significant undertakings […]